medigraphic.com
ISSN 1560-4381 (Print)

2020, Number 1

<< Back Next >>

Correo Científico Médico 2020; 24 (1)

Role of cytokines in the physiopathology of rheumatoid arthritis

Feria DGE, Leyva PCA, Concepción PW, Castro MAG, Larrea MIS

Language: Spanish
References: 31
Page:
PDF size: 420.79 Kb.


ABSTRACT

Rheumatoid arthritis is a chronic systemic disease of multifactorial etiology that affects the joints. Its physiopathology is not well known, but it indicates that there is a relevant role of cytokines as molecules which interrelate immune and neuroendocrine system disorders with environmental factors. This review describes the role of proinflammatory cytokines in the physiopathogenesis of rheumatoid arthritis and the practical application of this knowledge in the design of new medications for the treatment of this disease. For this work MedLine, MedicalKey and SciELO databases were reviewed with the descriptors cytokines and rheumatoid arthritis in Spanish and English. They were filtered mainly for quotable articles published in the last 5 years. Cuban biomedical journals were also reviewed.


REFERENCES

  1. Sansaricq Coto I, Céspedes Miranda EM, Molinet Fuertes EJ, Peña Sánchez M. Indicadores biológicos y de estrés oxidativo en la evolución de pacientes con artritis reumatoide. Rev Cubana Reumatol. 2015 [citado 10/11/ 2019] ; 17( 2 ): 132-138. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962015000200006&lng=es

  2. Mendoza Coussette U, Alonso Biosca ME. Predicción del riesgo coronario en la Artritis Reumatoide mediante variables asociadas a su actividad inmunológica. Rev Cubana Invest Bioméd. 2018 [citado 12/09/2019];37(2). Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/184

  3. Martínez-Ferrer A, Aguilar Zamora M, Montolio Chiva L, Valls Pascual E, Ybáñez García D, Alegre Sancho JJ. Tofacitinib una nueva molécula en el tratamiento de la artritis reumatoide. Rev Sociedad Val Reuma. 2018[citado 10 /11/2019]; 7(3):12-18. Disponible en: https://dialnet.unirioja.es/descarga/articulo/6492812.pdf

  4. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018[citado 02/10/2019]; 30(2): 207–214. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805125/pdf/corhe-30-207.pdf

  5. 5.Carrión M, Frommer KW, Pérez-García S, Müller-Ladner U, Gomariz RP, Neumann E. The Adipokine Network in Rheumatic Joint Diseases. Int J Mol Sci. 2019[citado 02/10/2019]; 20: 4091. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747092/pdf/ijms-20-04091.pdf

  6. Malemud CJ. Defective T-Cell Apoptosis and T-Regulatory Cell Dysfunction in Rheumatoid Arthritis. Cells. 2018[citado 02/10/2019]; 7: 223. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316166/pdf/cells-07-00223.pdf

  7. Chang MH, Nigrovic PA. Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight. 2019[citado02/10/2019]; 4(5):e125278. Disponible en: https://insight.jci.org/articles/view/125278/pdf

  8. Zhang L, Ouyang H, Xie Z, Liang ZH, Wu XW. Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. Exp Mol Med. 2016[citado 02/10/ 2019]; 48: 228. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855274/pdf/emm201612a.pdf

  9. Tateiwa D, Yoshikawa H, Kaito T. Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review. Cells. 2019[citado 02/10/ 2019]; 8: 818. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721572/pdf/cells-08-00818.pdf

  10. Put S, Westhovens R, Lahoutte T, Matthys P. Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques. Arthritis Res Ther. 2014 [citado 02/10/ 2019]; 16(2):208. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25099015

  11. González Costa M, González Alexander AP. La inflamación desde una perspectiva inmunológica: desafío a la Medicina en el siglo XXl. Rev Habanera Cienc Méd. 2019 [citado 02/10/ 2019] ; 18( 1 ): 30-44. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729519X2019000100030&lng=es

  12. Kim KW, Kim HR, Kim BM Cho ML, Lee SH. Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis. Am J Pathol 2015[citado 02/10/ 2019]; 185(11): 3011-3024. Disponible en: http://dx.doi.org/10.1016/j.ajpath.2015.07.017

  13. Bui VL, Brahn E. Cytokine targeting in rheumatoid arthritis. Clin Immunol. 2019[citado 02/10/ 2019]; 206: 3-8. Disponible en: https://doi.org/10.1016/j.clim.2018.04.001

  14. Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Biomedicine Pharmacotherapy. 2017[citado 02/10/ 2019]; 92: 615–633.Disponible en: http://dx.doi.org/10.1016/j.biopha.2017.05.055

  15. Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019[citado citado 02/10/2019];33: 15–32. Disponible en: https://doi.org/10.1007/s40259-019-00333-w

  16. Borriello F, Galdiero MR, Varricchi G, Loffredo S, Spadaro G, Marone G. Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. Int J Mol Sci. 2019[citado 02/10/ 2019]; 20: 834. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412223/pdf/ijms-20-00834.pdf

  17. Coury F, Peyruchaud O, Machuca-Gayet I. Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases. Front Immunol. 2019[citado 02/10/ 2019]; 10: 679. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456657/pdf/fimmu-10-00679.pdf

  18. Mendez-Rayo T, Ochoa-Zárate L, Posso-Osorio I, Ortiz E, Naranjo-Escobar J, Tdbón Gabriel J. Interpretación de los autoanticuerpos en enfermedades reumatológicas. Rev Colomb Reumatol. 2018 [citado 02/10/ 2019]; 25(2): 112-125. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232018000200112&lng=es

  19. Fang Q, Ou J, Nandakumar KS. Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis. Mediators Inflamm. 2019[citado 02/10/ 2019]; 2019: 6363086. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854956/pdf/MI2019-6363086.pdf

  20. Bugatti S, Manzo A, Montecucco C, Caporali R. The Clinical Value of Autoantibodies in Rheumatoid Arthritis. Front Med (Lausanne) 2018[citado 02/10/ 2019]; 5: 339. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287017/pdf/fmed-05-00339.pdf

  21. Hernández-Bello J, Baños-Hernández CJ, Palafox-Sánchez CA, Navarro-Zarza JE, Reyes-Castillo Z, Muñoz Valle JF. Combinaciones de autoanticuerpos y su asociación con variables clínicas en artritis reumatoidea. Acta Bioquím Clín Latinoam. 2018 [citado 02/10/ 2019]; 52(1): 49-60. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S032529572018000100008&lng=es

  22. Muñoz-Grajales C, Muñoz Vahos CH, Díaz Betancur J, Ramírez Gómez LA. Frecuencia de anticuerpos antipéptido cíclico citrulinado y factor reumatoide en pacientes con enfermedades reumatológicas de un centro de reumatología, Medellín, Colombia. Rev Colombiana Reumatol. 2014 [citado 02/10/ 2019]; 21(4): 177-182. Disponible en: http://dx.doi.org/10.1016/j.rcreu.2014.10.001

  23. Hernández-Flórez D. Valor L. IL-6: su papel en la patogenia de la artritis reumatoide. Consecuencias clínicas. Reumatol Clin. 2018[citado 02/10/ 2019]; 14 (2): 7-10. Disponible en: https://www.reumatologiaclinica.org/es-pdf-X1699258X18628556

  24. Jung JY, Kim MY, Suh CH, Kim HA. Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. Pediatr Rheumatol. 2018[citado 02/10/ 2019]; 16(79):1-9 Disponible en: https://doi.org/10.1186/s12969-018-0296-z

  25. Evans‐Marin H, Rogier R, Koralov SB, Manasson J, Roeleveld D, van der Kraan PM. et al. Microbiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis. Arthritis Rheumatol. 2018[citado 02/10/ 2019]; 70(12): 1971–1983. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587816/pdf/ART-70-1971.pdf

  26. Serra López-Matencio JM, Morell Baladrón A, Castañeda S. JAK-STAT inhibitors for the treatment of immunomediated diseases. Medicina Clínica. 2019 [citado 02/10/ 2019]; 152 (9): 353-360. Disponible en: https://doi.org/10.1016/j.medcle.2019.02.017

  27. Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2019[citado 02/10/ 2019]; 13: 57–70. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304084/pdf/dddt-13-057.pdf

  28. Camacho Castillo KP, Martínez Verdezoto TD, Ortiz Granja LB, Urbina Aucancela KD. Artritis reumatoidea en el adulto mayor. Rev Cubana de Reumatolo. 2019 [citado 02/10/ 2019];21(3). Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/705

  29. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Maxime Dougados M. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017[citado 02/10/ 2019]; 76 (6): 960–977. Disponible en: http://dx.doi.org/10.1136/annrheumdis-2016-210715

  30. Cavalli G, Dinarello CA. Anakinra Therapy for Non-cancer Inflammatory Diseases. Front Faramacol. 2019[citado 02/10/ 2019]; 8(10):148. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232613/

  31. Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, O’Shea JJ. et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology . 2019[citado 02/10/ 2019]; 58(Suppl 1): 4–16. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657570/pdf/key432.pdf




2020     |     www.medigraphic.com